AnaptysBio (NASDAQ: ANAB) Faces Legal Uncertainty Amidst Upcoming Earnings and Financial Scrutiny

Font: Financial Modeling Prep  • May 09, 2026

• Legal Dispute & Royalty Rates: AnaptysBio, Inc. (NASDAQ: ANAB) is embroiled in an ongoing legal dispute with Tesaro regarding royalty rates for the cancer drug Jemperli, with a recent partial ruling dismissing Tesaro's claim but leaving the core dispute unresolved.
• Upcoming Earnings & Analyst Expectations: AnaptysBio is set to release its Q1 earnings on May 11, 2026, with varying analyst forecasts for EPS (e.g., -$0.64 to -$0.77) and revenue (e.g., $18.86 million to $27.5 million).
• Financial Health & Ratios: AnaptysBio exhibits a negative price-to-earnings (P/E) ratio of -145.60 and a high debt-to-equity ratio of 7.81, but a strong current ratio of 9.07 indicates robust short-term liquidity.

AnaptysBio is a biotechnology company that develops antibody-based treatments. Its work focuses on creating therapies for inflammation and immuno-oncology. A key area of focus is its collaboration with GSK plc (NYSE: GSK)'s subsidiary, Tesaro, over the cancer drug Jemperli, which is currently the subject of a legal dispute.

On May 11, 2026, AnaptysBio is set to release its quarterly earnings report. Analyst expectations vary, with some forecasting an earnings per share (EPS) of -$0.64 on $18.86 million in revenue. An EPS is a company's profit divided by its number of common shares, indicating profitability on a per-share basis.

Other forecasts, as highlighted by Zacks Investment Research, project a quarterly loss of $0.77 per share on revenues of $27.5 million. While this represents a nearly 40% improvement in earnings from the prior year, revenues are expected to decrease by 1%. The stock recently surged 14.8% to $58.88 after a favorable court ruling.

This ruling dismissed a claim by Tesaro, which protects AnaptysBio's royalty rates for Jemperli. However, as highlighted by Proactive Investors, a counterclaim by AnaptysBio was also dismissed. The core legal dispute between the companies over their license agreement is still unresolved and will proceed to trial, creating ongoing uncertainty.

Financially, AnaptysBio shows a negative price-to-earnings (P/E) ratio of -145.60, meaning it is not currently profitable. The company has a high debt-to-equity ratio of 7.81, indicating significant debt. However, its current ratio of 9.07 suggests it has a strong ability to meet its short-term financial obligations.